chrisvoncsefalvay/vaers-outcomes huggingface dataset:
my husband goes a positive test result for covid; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (my husband goes a positive test result for covid) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Aug-2021, the patient experienced COVID-19 (my husband goes a positive test result for covid). At the time of the report, COVID-19 (my husband goes a positive test result for covid) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Aug-2021, SARS-CoV-1 test: positive (Positive) positive test result.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant history was not reported.  Treatment history was not provided.
Rash at injection site, followed by fever and chills through the night. Swelling and soreness at injection site and mild bronchitis following day.
Started with odd breathing and hives 12 hours after vaccines - initially seen in ER (no meds given).  At F/U 24 hours vaccine had extensive urticaria.  BENADRYL received.
Everyday dizziness/vertigo, nausea/vomiting, balance problems, extreme motion sensitivity, disoriented, confused, unsteady, sensitive to light and sound.
After 5 min of receiving the vaccine, client became diaphoretic, pallor observed and reported numbness to bilateral hands. BP taken using manual cuff at 14:26 hrs and recorded 68/42, HR 51 bpm with O2 saturation of 98 % on RA. LCTA, S1 and S2 audible to L apex 4th intercostal space.  Water was provided to the client. EMS was notified; EKG was obtained. Last V/S: BP of 103/68, HR of 79 bpm and RR of 18.  Client declined EMS care and declined to go to the hospital. Client was discharged home with wife; ambulated to car with steady gait. Alert/ Oriented x 3.
Patient received 2009 H1N1 in (L) deltoid at 12pm. Pt stated after injection started feeling fatigue, later, that evening around 9:00pm patient notice top lip(s) swollen & itching. OTC BENADRYL taking to counter effect, at this time meds seems to be effective.
Patients have been administered from vaccines that experienced a T excursion; Patients have been administered from vaccines that experienced a T excursion; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered from vaccines that experienced a T excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered from vaccines that experienced a T excursion) in a 31-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 027L21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Mar-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 10-Mar-2022, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered from vaccines that experienced a T excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered from vaccines that experienced a T excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered from vaccines that experienced a T excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered from vaccines that experienced a T excursion) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported. Max Temperature reached was 64°F Excursion duration was approximately 7 hours Three was no changes in visual inspection. It was reported patient had not any adverse events post injection. No treatment information was reported.
2 inch diameter hives-like with itching and slight swelling. Started next day and I still have it at area of injection.
expired doses administered to 2 patients; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired doses administered to 2 patients) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (expired doses administered to 2 patients). On 27-Jan-2022, EXPIRED PRODUCT ADMINISTERED (expired doses administered to 2 patients) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   It was reported that the patient received his booster vaccine after 5 days of its expiry and had no other symptoms experienced. It was also stated that the vial was initially stored in the refrigerator and there were no temperature excursions. Concomitant and treatment medication information was not reported.    This case was linked to MOD-2022-462691 (Patient Link).
Bilious vomiting, possible bowel obstruction. Secondary to possible stricture. Patient has remote history of necrotizing enterocolitis as a newborn (not surgically treated). Patient currently hospitalized.  Nurse follow up on 08/10/04 states: "Diarrhea." Per annual report-Patient had 2 "no show" appointments since reaction last on e 8/2/04.  Not seen at RMCHCS since then.
This case was reported by a consumer via call center representative and described the occurrence of headache in a patient who received TWINRIX for prophylaxis. On an unknown date, the patient received the 1st dose of TWINRIX. On an unknown date, less than a year after receiving TWINRIX, the patient experienced headache, fever, vomiting and general body pain. On an unknown date, the outcome of the headache, fever, vomiting and general body pain were recovered/resolved. It was unknown if the reporter considered the headache, fever, vomiting and general body pain to be related to TWINRIX. Additional details were provided as follows: The age at vaccination was not provided. On unknown date in the spring of 2008, the patient was vaccinated with the dose of TWINRIX, when the patient was a student at state university. The patient had a pretty significant reaction after the receiving the vaccine that caused a severe headache, fever, vomiting and body ache all of which lasted for around 7 days. For which, the patient had the multiple trips to physician at hospital. At the time of reporting, the patient works in the public health field now at a local health department dealing with restaurants, nursing homes, and child care centers. The patient had always been exempted for not being vaccinated due to its past reaction in 2008. The patient would like to be vaccinated against both but would never take the TWINRIX vaccine, due to the history and fear of another reaction as being more severe next time. The patient had done inquiry that does that vaccine contain an ingredient or preservative that were not in separate Hepatitis A and Hepatitis B vaccines. The patient could possibly be immunized with or do the physician recommend any other Hepatitis A and Hepatitis B vaccines to people who like myself had adverse reactions to TWINRIX. The reporter had given the permission for follow up.
Fever, aches, not feeling well, Had not consulted physician for 3 day since shot. Recommended patient consult with physician.
pt recv vax;mom called;pt crying w/ pain in rt arm;apap given;pt v&abd cramps;came to ofc w/mild T,entire upper arm red,hurt but hot,significantly indurated;recommended ice packs;27apr mom reports pt using arm normally w/ tenderness;
2-7-18 rash on lower abd. x 3 days. Red but not warm. 2-9-18 raised red hard area at injection site 4.5cm x 3cm area and fever treated with Cephalexin. 2-12-18 improved no redness.
PATIENT RECEIVED PFIZER BIVALENT AS FIRST, PRIMARY DOSE OF COVID VACCINE SERIES
She was apprehensive to begin with as she had fainted/lost consciousness in the past with the first dose of Gardasil in the past and since then has not had vaccinations. She developed tachycardia with a heart rate between 130 and 160 beats per minute. She was in sinus rhythm. She denied chest pain, but was feeling the palpitations. She was unable to focus on the breath as the heart rate was not going down, she requested to be transported to the Hospital. We called the on-site paramedics from our fire department and an ambulance arrived and transported her to Hospital.
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date.; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date.; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date.) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date.) in a 43-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Feb-2022 at 4:50 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. In December 2021, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date.). On 21-Feb-2022 at 4:50 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date.) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications information was reported.  Patient received the booster dose.  This vaccine was administered up until its manufacturer expiry date of 04-Apr-2022.  No treatment medications were provided.
Shot was administered on Tues 7/1, noticed increased redness, soreness as of 7/2, warmness did not take oral med or use topical treatment. Pt went to urgent care MD who prescribed KEFLEX and NORCO.
This spontaneous report as received from a registered nurse, refers to a 19 year old female patient. Patient's pertinent medical history, concurrent condition and concomitant medication were not reported. No previous drug reactions/ allergies were reported. On 11-JUL-2016, the patient was vaccinated with first dose of GARDASIL 9 and on 04-AUG-2017, she received her second vaccine dose (lot # M007728, expiry date 21-MAR-2018) for prophylaxis (inappropriate schedule of drug administration). No adverse effects were reported. Additional information has been requested.
Nodule at injection site , painful when rubbed; Pain at injection site,  has lessened significantly/nodule is painful when rubbed; Arm pain, primarily at elbow; having pain in the left arm, primarily at the elbow; Myalgia in legs, feet, arm, upper left side of the back; Fatigue; This case was reported by a consumer via call center representative and described the occurrence of injection site nodule in a 76-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 18th January 2023, the patient received the 2nd dose of Shingrix. On 19th January 2023, 1 days after receiving Shingrix, the patient experienced injection site nodule, injection site pain, pain in arm, pain in elbow, myalgia and fatigue. On an unknown date, the outcome of the injection site nodule, pain in arm, pain in elbow and myalgia were not recovered/not resolved and the outcome of the injection site pain was recovering/resolving and the outcome of the fatigue was recovered/resolved.   It was unknown if the reporter considered the injection site nodule, injection site pain, pain in arm, pain in elbow, myalgia and fatigue to be related to Shingrix.     Additional Information: GSK Receipt Date: 24-JAN-2023 Reporter's comment: The caller was the patient. She had reported of receiving second dose of Shingrix in the left arm. She had experienced pain at the injection site, a nodule at the injection site, fatigue, myalgia, and arm pain and all the symptoms began the day after dose was received, on 19 January 2023. She had reported that, the fatigue had resolved after two days. She had reported all other symptoms were ongoing at the time of reporting.  She had experienced myalgia in the legs, feet, arm, and upper, left side of the back.  She had reported of having pain in the left arm, primarily at the elbow. She had reported that, the nodule was painful when rubbed. She had reported that, the pain at injection site had lessened significantly. She had reported that, all the other symptoms had been consistent, meaning they have gotten no better or worse since the onset.  The reporter did not consent to follow-up.
episode of lethargy, unresponsive staring & eyes rolling for 30min, thigh swollen tender;seen @ hosp
This case was reported by a pharmacist via call center representative and described the occurrence of fever in a 71-year-old female patient who received SHINGRIX (batch number 5MG5E, expiry date 5th May 2021) for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced fever. On an unknown date, the outcome of the fever was recovered/resolved. It was unknown if the reporter considered the fever to be related to SHINGRIX. Additional case details were reported as follows: The age at vaccination was not reported. The reporter called to report that, patient had fever for a few hours after SHINGRIX immunization. The batch number reported for SHINGRIX (5MG5F), did not exist and was updated to 5MG5E, as per sales database.
Throbbin pain at injection site and arm feels heavy since receiving flu shot.  States this occurred also in 2 previous years after having received flu shots.  Instructed to see her private MD
shingles; Information has been received from a lawyer regarding a case in litigation referring to a female patient (pt) of unknown age. The pt's concurrent conditions, medical history and concomitant medications were not reported. On or about 07-OCT-2016, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (dosage regimen, route of administration, lot number and expiration date were not provided) as prescribed and/or administered by a pharmacist for the long-term prevention of shingles and/or zoster-related conditions. Subsequent to the pt's inoculation, she was treated by a healthcare provider at a hospital, for shingles. As a direct and proximate result of the pt's use of zoster vaccine live (ZOSTAVAX), she had and would continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of shingles was not provided, and causal relationship was reported as related to zoster vaccine live (ZOSTAVAX).
Information has been received from a medical assistant via a company representative referring to a female patient of unknown age. On an unknown date the patient as vaccinated with the first dose of GARDASIL 9 (dose and frequency were not reported) intramuscularly (reported as per label). On an unknown date the patient experienced fainted. The patient stayed at the office for an unspecified amount of time after she fainted. The patient did not experience any injuries from fainting. The patient did receive the complete GARDASIL 9 series on unspecified dates. The outcome of the event was reported as recovered/resolved (unspecified date). Causality was not reported. Additional information has been requested.
Shoulder injury related to vaccine administration. Developed frozen shoulder within 24 hrs after vaccine administration.
did not confirm age at time of scheduling appointment . Patient is 16 years of age and recommended age group is 18- older .
Lip numbness at 30 minutes after injection; facial tingling. 50 mg Benadryl given and OTC Pepcid
dizziness 5 minutes after vaccination.  no other symptoms released after 35 minutes.  completely resolved
Rash-upper torso red, flat, discrete, round lesions; began morning after, non-itching, no treatment. Hx similar episode with medication change-BP meds.
Patient reported painful injection site Mon. and Tuesday. Went to emergency room. Treated with IV antibiotics and 2-3 oral antibiotics. Pt. was told by ER doctor this is from injection received on Monday for ZOSTAVAX. Diagnosis - cellulitis. Currently monitored by MD.
Information received from a nurse reports the pt is a hemodialysis pt who did not seroconvert after the 3rd dose of hepatitis B, the pt experienced muscle soreness, he experienced shoulder pain that radiated down the R arm to hand and between his thumb and index finger. The area between this thumb and index finger appeared puffy, sometimes radiated into the opposite shoulder, also had neck pain.
DTaP vaccination on 3/27/17. 3/29/17 mother called redness around injection site. 4/3/17 -mother called - child developed hives around injection site 5 days later and hives progressed to whole body. (verified by photo).
On 3/29 inch and a half redness in diameter and slight tenderness at site of injection. On 3/30 small hives on lower back noticed at 7:30 pm. At 1:30 am almost her entire back was covered in huge hives. Gave one dose of Benadryl and all hives were gone in the morning.
Vomiting started immediately after vaccinations and continued every 20-40 minutes for 3 hours until taking ZOFRAN.
After booster, severe stomach pain and diarrhea. Next day, pressure and ?twitching in heart?. Lasting for several days. Pressure on heart. Shortness of breath. Pain/discomfort. Radiates around to upper back. Reporting on behalf of  my 23-year-old son who is a healthy and a new nurse. He has been  suffering and thought he was having a heart attack. Went to a walk in facility one night after work and they told him it was anxiety. Pain and discomfort has persisted - we did not know until we researched this was a side affect. A few days ago, he also had shortness of breath and dizziness.  We thought the vaccine had inflamed his asthma.  His symptoms are starting to improve but will still have him checked by cardio doctor before strenuous exercise.  If there is some hotline where we can call or the doctor can call, please let us know. In this small town, I don?t think these doctors see cases like this - young healthy males having a reaction to the vaccine.
fever on 19JUN & 20JUN temp not taken;motrin given;fever went away;rash appeared on 21JUN;raised, mosquito bite looking, on trunk & couple on face & arms;
THE VACCINE ADMINISTERED WAS FOR 2 TO LESS THAN 5 YEARS OLD GIVE TO A 5 YEARS OLD CHILD
Presented with chest pain, diaphoresis, nausea and vomiting with left shoulder numbness. Found to have STEMI, 100% occlusion of RCA on LHC s/p PCI to culprit lesion. Started on ACEi, beta blocker
After taking my medicine that day I started to receive head aches, body cramps, asthma flareups, extreme jitters, nausea/vomiting, over heating, chills and dizziness   I Just had the second dose and notice the same reactions as last time taking place an hour after I had taken my medication that day (Nausea, lightheadedness/dizziness, chills asthma flare ups and cramps) .  For both of these instances I took Dayquil and had to take and albuterol sulfate treatment on my nebulizer for the asthma attack. During the first shot: The jitters, body aches and overheating continued throughout the night but subsided 12 hours later at 3PM the next day. For the second shot the symptoms didn't last as long with them subsiding around 4am
The patient is a 56 yo male with a history of CHF CRI OSA HTN who presents for adverse event evaluation after receipt of PPSV23 on 10 Jul 2015 (lot# K004487 mfx MSD) consisting of continued severe myalgias, stiffness, fatigue and weakness. He denies any symptoms of immediate hypersensitivity reaction of urticarial lesions, increased heart rate, chest pain, shortness of breath or oral/facial/throat swelling. He states he developed localized pain at the injection site within 10 minutes of vaccine receipt. He was at work and within hours developed alternating chills and "hot" flashes, nausea and fatigue. That evening his wife states he had fever of 99.9 which was treated with OTC ibuprofen. He states he felt worse the next day with notable fatigue, weakness and pain. He had localized weakness to the left arm which he had difficulty "lifting" but denies paralysis or paresis. He had generalized pain to both arms, the right being worse, right leg and low back which he describes as sharp, aching, stabbing "I felt like a bull kicked me". He states he experienced stiffness to lower extremities, especially on the left, particularly to muscles in lower legs, (R) hip, and left shoulder. He denies knee stiffness. He believes he continued fevers intermittently but did not take any temperatures. He states he developed a "knot" adjacent to the injection site (medially) which has not fully resolved but denies noting local erythema or edema. He developed chest pain and was admitted for cardiac eval on 19 Jul 2015. He was diagnosed with polymyalgia rheumatica and treated with oral prednisone and released which he states does not help. He currently continues with severe pain myalgias, weakness and stiffness and has been prescribed TYLENOL with codeine which he has taken only a few doses and feels it does not help. He states MOTRIN is effective but is concerned to take it due to his HF. He continues nausea and poor appetite and has lost approximately 8 pounds. He is activity intolerant and is unable to work. His sleep is disrupted due to pain, has difficulty turning in bed and he feels very fatigued. P: He was diagnosed with Polymyalgia Rheumatica, received oral steroid therapy which has not helped, although he experiences benefit from NSAID, but is not taking these due to CHF and CRI. His lab work demonstrates a significantly elevated ESR of 110 and an elevated RF of 18. He also demonstrated a microcytic anemia, and alk phos of 435. In chart review he also has an elevated PSA of 16 last drawn in 2013. He has a referral for rheumatology evaluation pending. His clinical history is inconsistent with a hypersensitivity reaction. His symptoms and ESR and RF factor are suggestive of a rheumatologic disorder, although he has not improved on oral steroids which is inconsistent with PMR. His symptoms are not strongly suggestive of Giant Cell Arteritis, although his ESR is concerning. The acute onset of his symptoms are inconsistent with new antibody.
Received flu shot on 11/3/99 at 10:30 am and by 2:00 pm was experiencing double vision which is still occuring. Per follow-up, the pt is 95% recovered. Pt suffers from slight diplopia.